These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 9519421)

  • 21. Diets with either beef or plant proteins reduce risk of calcium oxalate precipitation in patients with a history of calcium kidney stones.
    Massey LK; Kynast-Gales SA
    J Am Diet Assoc; 2001 Mar; 101(3):326-31. PubMed ID: 11269613
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Introduction of an enzyme method for determining pyrophosphate in urine--a comparative study between patients with calculi and normal probands].
    Genester C; Salgado J; Coll R; Conte A; Grases F
    Z Urol Nephrol; 1989 Jul; 82(7):369-73. PubMed ID: 2549749
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Metabolic urinary correlates of calcium oxalate dihydrate in renal stones.
    Asplin JR; Lingeman J; Kahnoski R; Mardis H; Parks JH; Coe FL
    J Urol; 1998 Mar; 159(3):664-8. PubMed ID: 9474121
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Changes in urinary stone risk factors in hypocitraturic calcium oxalate stone formers treated with dietary sodium supplementation.
    Stoller ML; Chi T; Eisner BH; Shami G; Gentle DL
    J Urol; 2009 Mar; 181(3):1140-4. PubMed ID: 19152919
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Body size and 24-hour urine composition.
    Taylor EN; Curhan GC
    Am J Kidney Dis; 2006 Dec; 48(6):905-15. PubMed ID: 17162145
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Modulation by calcium of the inhibitor activity of naturally occurring urinary inhibitors.
    Zerwekh JE; Hwang TI; Poindexter J; Hill K; Wendell G; Pak CY
    Kidney Int; 1988 May; 33(5):1005-8. PubMed ID: 3134570
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Preservation of urine samples for metabolic evaluation of stone-forming patients.
    Ferraz RR; Baxmann AC; Ferreira LG; Nishiura JL; Siliano PR; Gomes SA; Moreira SR; Heilberg IP
    Urol Res; 2006 Oct; 34(5):329-37. PubMed ID: 16896690
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical significance of phosphate in calcium oxalate renal stones.
    Ohman S; Larsson L; Tiselius HG
    Ann Clin Biochem; 1992 Jan; 29 ( Pt 1)():59-63. PubMed ID: 1536527
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Urinary citrate excretion in idiopathic nephrolithiasis.
    Ratan SK; Bhatnagar V; Mitra DK; Basu N; Malhotra LK
    Indian Pediatr; 2002 Sep; 39(9):819-25. PubMed ID: 12368525
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lithogenic risk factors for renal stones in patients with Crohn's disease.
    Buño Soto A; Torres Jiménez R; Olveira A; Fernández-Blanco Herraiz I; Montero García A; Mateos Antón F
    Arch Esp Urol; 2001 Apr; 54(3):282-92. PubMed ID: 11432047
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Study of calcium oxalate crystalluria on renal and vesical urines in stone formers and normal subjects.
    Robert M; Boularan AM; Delbos O; Guiter J; Descomps B
    Urol Int; 1998; 60(1):41-6. PubMed ID: 9519420
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Calcium oxalate crystallization in undiluted postprandial urine of healthy male volunteers as influenced by citrate.
    Fan J; Schwille PO; Schmiedl A; Fink E; Manoharan M
    Arzneimittelforschung; 2001 Oct; 51(10):848-57. PubMed ID: 11715639
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Urinary lithogen risk test: usefulness in the evaluation of renal lithiasis treatment using crystallization inhibitors (citrate and phytate).
    Conte A; Pizá P; García-Raja A
    Arch Esp Urol; 1999; 52(1):94-9. PubMed ID: 10101897
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Factors affecting calcium oxalate dihydrate fragmented calculi regrowth.
    Costa-Bauzá A; Perelló J; Isern B; Sanchis P; Grases F
    BMC Urol; 2006 Jul; 6():16. PubMed ID: 16822299
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of urine pH and magnesium on calcium oxalate saturation.
    Ferrè S; Grange JS; Adams-Huet Ms B; Moe OW; Maalouf NM
    Magnes Res; 2017 Nov; 30(4):107-119. PubMed ID: 29637896
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Thiazides reduce brushite, but not calcium oxalate, supersaturation, and stone formation in genetic hypercalciuric stone-forming rats.
    Bushinsky DA; Asplin JR
    J Am Soc Nephrol; 2005 Feb; 16(2):417-24. PubMed ID: 15647340
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of factors involved in calcium stone formation.
    Abraham PA; Smith CL
    Miner Electrolyte Metab; 1987; 13(3):201-8. PubMed ID: 3627051
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Citrate and renal stones].
    del Valle EE; Spivacow FR; Negri AL
    Medicina (B Aires); 2013; 73(4):363-8. PubMed ID: 23924538
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Role of the diurnal variation of urinary pH and urinary calcium in urolithiasis: a study in outpatients.
    Murayama T; Sakai N; Yamada T; Takano T
    Int J Urol; 2001 Oct; 8(10):525-31; discussion 532. PubMed ID: 11737477
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Increased dietary oxalate does not increase urinary calcium oxalate saturation in hypercalciuric rats.
    Bushinsky DA; Bashir MA; Riordon DR; Nakagawa Y; Coe FL; Grynpas MD
    Kidney Int; 1999 Feb; 55(2):602-12. PubMed ID: 9987084
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.